<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253068</url>
  </required_header>
  <id_info>
    <org_study_id>MK-3475-IIT-55441</org_study_id>
    <nct_id>NCT03253068</nct_id>
  </id_info>
  <brief_title>Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wakayama Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in
      subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro) plus
      amurubicin (AMR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open, uncontrolled, multi-center, phase II study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Imaging will be performed every 6 weeks through study completion, an average of 6 months</time_frame>
    <description>Overall response rate will be assessed using RECIST ver1.1 by investigators</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Small Cell Lung Cancer Extensive Stage</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab plus amurubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab plus amurubicin</intervention_name>
    <description>Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks</description>
    <arm_group_label>Pembrolizumab plus amurubicin</arm_group_label>
    <other_name>Keytruda, calsed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a histologically or cytologically confirmed diagnosis of SCLC.

          2. Confirmed radiological relapse within 90 days from the last day of first-line
             chemotherapy.

          3. Have adequate tumor tissue sample to test PD-L1 immunohistochemistry.

          4. Have measurable disease based on RECIST 1.1 as determined by the site.

          5. Be ≥20 years of age on day of signing informed consent.

          6. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group

          7. Have adequate organ function as indicated by the following laboratory values

          8. Is expected to live more than 90 days.

          9. Be willing and able to provide written informed consent/assent for the trial.

         10. Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours from registration.

         11. Female subjects of childbearing potential must be willing to use an adequate method of
             contraception as outlined in Section 5.7.2 - Contraception, for the course of the
             study through 120 days (or longer as specified by local institutional guidelines)
             after the last dose of study medication.

         12. Male subjects of childbearing potential must agree to use an adequate method of
             contraception as outlined in Section 5.7.2- Contraception, starting with the first
             dose of study therapy through 120 days (or longer as specified by local institutional
             guidelines) after the last dose of study therapy.

        Exclusion Criteria:

          1. Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigation device
             within 30 days from registration.

          2. Is receiving systemic steroid therapy ≤ 3 days from registration or receiving any
             other form of immunosuppressive medication.

          3. Has received prior systemic cytotoxic chemotherapy, biological therapy, OR major
             surgery within 3 weeks of the first dose of trial treatment; received thoracic
             radiation therapy of &gt; 30 Gy within 6 months from registration.

          4. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody.

          5. Has symptomatic central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          6. Active autoimmune disease that has required systemic treatment in past 2 years (i.e.
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).

          7. Has had an allogeneic tissue/solid organ transplant.

          8. History of noninfectious pneumonitis that required steroids or current active
             pneumonitis, or any evidence of interstitial lung disease by CT scan.

          9. Has received or will receive a live vaccine within 30 days from registration.

         10. Has an active infection requiring intravenous systemic therapy and oral
             administration.

         11. Has known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

         12. Has known active Hepatitis B, or Hepatitis C.

         13. Has any history of prior malignancy, with the exception of basal cell carcinoma of the
             skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ
             cervical cancer, or has undergone potentially curative therapy with no evidence of
             that disease recurrence for 5 years since initiation of that therapy.

         14. Has Known history of serious allergy.

         15. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

         16. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         17. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days (or longer as specified by local institutional guidelines) after the
             last dose of trial treatment.

         18. Hypersensitivity or allergy to pembrolizumab or any of its excipients, and/or to AMR
             or any of its excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Akamatsu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Department of Internal Medicine, Wakayama Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nobuyuki Katakami, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Integrated Oncology, Institute of Biomedical Research and Innovation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuhiko Nakagawa, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical Oncology, Kinki University, Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiroaki Akamatsu, M.D.</last_name>
    <phone>+81-73-447-2300</phone>
    <email>h-akamat@wakayama-med.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nobuyuki Yamamoto, M.D., Ph.D.</last_name>
    <phone>+81-73-447-2300</phone>
    <email>nbyamamo@wakayama-med.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroaki Akamatsu, M.D.</last_name>
      <phone>+81-73-441-0619</phone>
      <email>h-akamat@wakayama-med.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Nobuyuki Yamamoto, M.D., Ph.D.</last_name>
      <phone>+81-73-441-0619</phone>
      <email>nbyamamo@wakayama-med.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wakayama Medical University</investigator_affiliation>
    <investigator_full_name>Hiroaki Akamatsu</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

